{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:16:46Z","timestamp":1778879806958,"version":"3.51.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:44:06Z","timestamp":1772228646000},"page":"417-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Populations"],"prefix":"10.1016","volume":"30","author":[{"given":"Robert J.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cld.2026.01.005_bib1","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020","volume":"22","author":"Kalligeros","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib6","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib8","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study","volume":"54","author":"Bhala","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.7869\/tg.120","article-title":"Risk of development of hepatocellular carcinoma in patients with NASH-related cirrhosis","volume":"34","author":"Amarapurkar","year":"2013","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.005_bib11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1665-2681(19)30845-2","article-title":"Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort","volume":"13","author":"Paranagua-Vezozzo","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-1746.2008.05640.x","article-title":"Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C","volume":"24","author":"Yatsuji","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.cld.2026.01.005_bib14","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.01.005_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ajg.2011.327","article-title":"Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma","volume":"107","author":"Kawamura","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.005_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/jgh.14448","article-title":"Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients","volume":"34","author":"Ito","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib17","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3748\/wjg.v24.i13.1440","article-title":"Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis","volume":"24","author":"Kimura","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.005_bib18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hep.28253","article-title":"Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study","volume":"63","author":"Wong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib19","article-title":"Association between non-alcoholic fatty liver disease and cancer incidence rate","author":"Kim","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib20","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ijc.30784","article-title":"The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease","volume":"141","author":"Lee","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cld.2026.01.005_bib21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.30858","article-title":"Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease","volume":"71","author":"Yang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gut.2004.052167","article-title":"Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study","volume":"54","author":"Davila","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cld.2026.01.005_bib23","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jebm.12270","article-title":"Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: an updated systematic review of 81 epidemiological studies","volume":"10","author":"Abdel-Rahman","year":"2017","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.cld.2026.01.005_bib25","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1053\/j.gastro.2004.09.020","article-title":"Alcohol and hepatocellular carcinoma","volume":"127","author":"Morgan","year":"2004","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2026.01.005_bib26","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1053\/j.gastro.2024.02.032","article-title":"Impact of longitudinal alcohol use patterns on long-term risk of cirrhosis among US veterans with steatotic liver disease","volume":"166","author":"Wong","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.01.005_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.31113","article-title":"PNPLA3 genotype and risk of liver and all-cause mortality","volume":"71","author":"Stender","year":"2020","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2026.01.005_bib28","doi-asserted-by":"crossref","first-page":"E139","DOI":"10.1002\/mc.22057","article-title":"Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction","volume":"52","author":"Hassan","year":"2013","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.cld.2026.01.005_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.005_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib32","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib33","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/HEP.0000000000000872","article-title":"Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019","volume":"80","author":"Danpanichkul","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib34","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.01.005_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis","volume":"77","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cld.2026.01.005_bib37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis","volume":"73","author":"Wolf","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib38","article-title":"What to do about hepatocellular carcinoma: recommendations for health authorities from the International Liver Cancer Association","volume":"4","author":"Allaire","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.01.005_bib39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/HEP.0000000000000953","article-title":"HES V2.0 outperforms GALAD for detection of HCC: a phase 3 biomarker study in the United States","volume":"81","author":"El-Serag","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib40","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jhep.2021.05.008","article-title":"Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease","volume":"75","author":"Younes","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2022.11.003","article-title":"Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis","volume":"78","author":"Nahon","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib42","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2024.10.035","article-title":"Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis","volume":"168","author":"Fujiwara","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.01.005_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.30129","article-title":"Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial","volume":"69","author":"Singal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2022.08.036","article-title":"Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era?","volume":"78","author":"Parikh","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000506834","article-title":"A comparison of biannual two-phase low-dose liver CT and US for HCC Surveillance in a Group at high risk of HCC development","volume":"9","author":"Yoon","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.cld.2026.01.005_bib46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2024.03.048","article-title":"Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC","volume":"81","author":"Kim","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib47","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","article-title":"Liver transplantation for Hepatocellular Carcinoma. Working Group report from the ILTS transplant oncology consensus conference","volume":"104","author":"Mehta","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2026.01.005_bib48","article-title":"Evolution of liver transplantation indications: expanding Horizons","volume":"60","author":"Battistella","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.cld.2026.01.005_bib49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ncp.10449","article-title":"Evolution of NAFLD and its management","volume":"35","author":"Mundi","year":"2020","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.cld.2026.01.005_bib50","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.cgh.2021.11.004","article-title":"Clinical and patient-reported outcomes from patients with nonalcoholic Fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)\/non-alcoholic Fatty liver disease (NAFLD) registry","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib51","article-title":"Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: an Italian liver transplant registry study","volume":"6","author":"Vitale","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.01.005_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib53","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib54","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3748\/wjg.v29.i2.286","article-title":"Screening and interventions to prevent nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis-associated hepatocellular carcinoma","volume":"29","author":"Cernea","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2026.01.005_bib56","article-title":"MASLD-related HCC: multicenter study comparing patients with and without cirrhosis","volume":"6","author":"Vitellius","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2026.01.005_bib57","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.cgh.2024.03.028","article-title":"Phenotypes of Metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma","volume":"22","author":"Rivera-Esteban","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib58","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/lt.25202","article-title":"Predictors of ultrasound failure to detect hepatocellular carcinoma","volume":"24","author":"Samoylova","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2026.01.005_bib59","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.35097","article-title":"Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: a nationwide cohort study","volume":"156","author":"Vaz","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cld.2026.01.005_bib60","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1111\/jgh.16727","article-title":"Lower hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease: impact on treatment eligibility","volume":"39","author":"Henry-Blake","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib61","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.005_bib62","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2026.01.005_bib63","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/apt.70002","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) impacts long-term outcomes after curative-intent surgery for hepatocellular carcinoma","volume":"61","author":"Uluk","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.01.005_bib64","doi-asserted-by":"crossref","first-page":"704","DOI":"10.21037\/hbsn-22-291","article-title":"Obesity and its influence on liver dysfunction, morbidity and mortality after liver resection","volume":"12","author":"Kampf","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.cld.2026.01.005_bib65","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.005_bib66","first-page":"779","article-title":"Ten-Year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"Tabrizian","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cld.2026.01.005_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11648","article-title":"European Society of organ transplantation (ESOT) consensus report on downstaging, bridging and immunotherapy in liver transplantation for hepatocellular carcinoma","volume":"36","author":"Claasen","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.cld.2026.01.005_bib68","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.dld.2023.08.062","article-title":"Efficacy of immunotherapy in hepatocellular carcinoma: does liver disease etiology have a role?","volume":"56","author":"Pinto","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2026.01.005_bib70","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MEG.0000000000002914","article-title":"Metabolic dysfunction-associated steatotic liver disease correlates with higher lower graft survival in liver transplant recipients with hepatocellular carcinoma","volume":"37","author":"Alsaqa","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib71","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/TP.0000000000003867","article-title":"Management of diabetes in candidates for liver transplantation and in transplant recipients","volume":"106","author":"Brodosi","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2026.01.005_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/LVT.0000000000000007","article-title":"Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium","volume":"29","author":"Verna","year":"2023","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2026.01.005_bib73","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib74","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.3390\/cimb46060356","article-title":"MASLD-Related HCC: a comprehensive review of the trends, pathophysiology, tumor microenvironment, surveillance, and treatment options","volume":"46","author":"Shi","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.cld.2026.01.005_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105031","article-title":"Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma","volume":"101","author":"Wang","year":"2024","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.cld.2026.01.005_bib76","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/HEP.0000000000000786","article-title":"Molecular mechanisms in MASLD\/MASH-related HCC","volume":"82","author":"Wang","year":"2025","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2026.01.005_bib77","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/LVT.0000000000000568","article-title":"Differential aging trends among candidates for liver transplant with and without HCC","volume":"31","author":"Jutras","year":"2025","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2026.01.005_bib78","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.dld.2024.09.025","article-title":"Liver transplant for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease versus other etiologies: a meta-analysis","volume":"57","author":"Parente","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2026.01.005_bib79","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ehjqcco\/qcaa009","article-title":"Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years","volume":"6","author":"Koshy","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.cld.2026.01.005_bib80","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/lt.24738","article-title":"Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil","volume":"23","author":"D'Avola","year":"2017","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2026.01.005_bib81","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.cgh.2019.04.033","article-title":"Increased risk of death in first year after liver transplantation among patients with Nonalcoholic steatohepatitis vs liver disease of other etiologies","volume":"17","author":"Nagai","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299507","article-title":"Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis","volume":"19","author":"Gurun","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2026.01.005_bib83","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/lt.24100","article-title":"Evolution of serum atherogenic risk in liver transplant recipients: role of lipoproteins and metabolic and inflammatory markers","volume":"21","author":"Chhatrala","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2026.01.005_bib84","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/lt.24223","article-title":"De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients","volume":"21","author":"Idowu","year":"2015","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.cld.2026.01.005_bib85","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cgh.2024.09.041","article-title":"Lifestyle and pharmacologic approaches to prevention of Metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma","volume":"23","author":"Cheraghpour","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.005_bib86","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/TP.0000000000004875","article-title":"Minimizing metabolic and cardiac risk factors to maximize outcomes after liver transplantation","volume":"108","author":"Schmidt","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2026.01.005_bib87","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIR.0b013e31823eb07a","volume":"126","author":"Lentine","year":"2012","journal-title":"Circulation"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612600005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612600005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:57:14Z","timestamp":1778878634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932612600005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S108932612600005X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Special Populations","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}